Androgen therapy in the aging male

World Journal of Urology

Volumn 21, Issue 5, 2003, Pages 292-305

  Lunenfeld, Bruno ^a,b  

^a BAR ILAN UNIVERSITY   (Israel)

^b NONE   (Israel)

Author keywords

Aging male; Androgen replacement therapy; Androgens; Hypogonadism

Indexed keywords

ANDROGEN; TESTOSTERONE;

AGE; ALGORITHM; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; IMPOTENCE; LIBIDO; MALE; MUSCLE WEAKNESS; OSTEOPOROSIS; REVIEW;

AGE FACTORS; ALGORITHMS; ANDROGENS; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; IMPOTENCE; LIBIDO; MALE; MUSCLE WEAKNESS; OSTEOPOROSIS; TESTOSTERONE;

EID: 2442694169     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-003-0366-8     Document Type: Article

References (110)

1. Gray A, Berlin JA, McKinlay JB, Longcope C (1991) An examination of research design effects on the association of testosterone and male aging: results of a meta-analysis. J Clin Epidemiol 44:671-684
2. Gray A, Feldman HA, McKinlay, Longcope C (1991) Age, disease and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study J Clin Endocrinol Metabol 73:1016-1025
3. Morley JE, Kaiser FE, Perry HM III, Patrick P, Morley PMK, Stauber PM, Vellas B, Baumgartner RN, Garry PJ (1997) Longitudinal changes in testosterone, luteinizing hormone and follicle-stimulating hormone in healthy older men Metabolism 46:410-413
4. Harman SM, Metter EJ, Tobin JD, Pearson J Blackman MR (2001) Longitudinal effects of aging on serum total and free testosterone levels in healthy men. J Clin Endocrinol Metab 86:724-731
5. Kaufman JM, Vermeulen A (1997) Declining gonadal function in elderly men. Baillieres Clin Endocrinol 11:289-298
6. Boonen S, Vanderschueren D, Geusens P, Bouillon R (1997) Age-associated endocrine deficiencies as potential determinants of femoral neck (type II) osteoporotic fracture occurrence in elderly men. Int J Androl 20:134-143
7. Kenny AM, Prestwood KM, Marcello KM, Raisz LG (2000) Determinants of bone density in healthy older men with low testosterone levels. J Gerontol 55A:M492-M497
8. Morley JE, Kaiser FE, Sih R, Hajjar R, Perry III HM (1997) Testosterone and frailty. Clin Geriatr Med 13:685-694
9. Genant HK, Cann CE, Pozzi-Mucelli S, et al (1981) Vertebral mineral determination by quantitative CT: clinical feasibility and normative data. J Comput Assist Tomogr 7:554
10. Meier DE, Orwoll ES, Jones JM (1984) Marked disparity between trabecular and cortical bone loss with age in healthy men. Ann Intern Med 101:605-612
11. Ravaglia G, Forti P, Maioli F, et al (2000) Body composition, sex steroids, IGF-1 and bone mineral status in aging men. J Gerontol 55A:M516-M521
12. Beld AW van den, de Jong FH, Grobbee DE, Pols HAP, Lamberts SWJ (2000) Measures of bioavailable serum testosterone and estradiol and their relationships with muscle strength, bone density, and body composition in elderly men. J Clin Endocrinol Metab 85:3276-3282
13. Ongphiphadhanakul B, Rajatanavin R, Chailurkit L, et al (1995) Serum testosterone and its relation to bone mineral density and body composition in normal males. Clin Endocrinol 43:727-733
14. Greendale GA, Edelstein S, Barrett-Connor E (1997) Endogenous sex steroids and bone mineral density in older women and men: The Rancho Bernardo Study. J Bone Miner Res 12:1833-1843
15. Goldray D, Weisan Y, Jaccard N, et al (1993) Decreased bone density in elderly men treated with the gonadotropin-releasing hormone agonist decapeptyl (D-Tryp6-GnRH). J Clin Endocrinol Metab 76:288-290
16. Stanley HL, Schmitt BP, Poses RM, Deiss WP (1991) Does hypogonadism contribute to the occurrence of minimal trauma hip fracture in elderly men? J Am Gerontol Soc 39:766-771
17. Jackson JA, Riggs MW, Spiekerman AM (1992) Testosterone deficiency as a risk factor for hip fractures in men: a case-control study. Am J Med Sci 304:4-8
18. Abbasi AA, Rudman D, Wilson CR, Drinka PJ, Basu SN, Mattson DE, Richardson TJ (1995) Observations on nursing home residents with a history of hip fracture. Am J Med Sci 310:229-234
19. Amin S, Zhang Y, Sawin CT, et al (2000) Association of hypogonadism and estradiol level with bone mineral density in elderly men from the Framingham study. Ann Intern Med 133:951-963
20. Khosla S, Melton LJ, Atkinson EJ, O'Fallon WM (2001) Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab 86:3555-3561
21. Barrett-Connor E, Mueller JE, Mühlen DG von, et al (2000) Low levels of estradiol are associated with vertebral fractures in older men, but not women: The Rancho Bernardo Study. J Clin Endocrinol Metab 85:219-223
22. Baumgartner RN, Waters DL, Gallagher D, et al (1999) Predictors of skeletal muscle mass in elderly men and women. Mech Ageing Dev 107:123-136
23. Couillard C, Gagnon J, Bergeron J, et al (2000) Contribution of body fatness and adipose tissue distribution to the age variation in plasma steroid hormone concentrations in men: the HERITAGE Family Study. J Clin Endocrinol Metab 85:1026-1031
24. Gooren LJG (2001) Visceral obesity, androgens and the risk of cardiovascular disease and diabetes mellitus. Aging Male 4:30-38
25. Stellato RK, Horton ES, Feldman HA, McKinlay JB, Hamdy O (2000) Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men. Diabetes Care 23:490-494
26. Lee CD, Blair SN, Jackson AS (1999) Cardiorespiratory fitness, body composition, and all-cause cardiovascular disease mortality in men. Am J Clin Nutr 69:373-380
27. Perry HM, Miller DK, Patrick P, Morley JE (2000) Testosterone and leptin in older African-American men: relationship to age, strength, function, and season. Metabolism 49:1085-1091
28. Breuer B, Trungold S, Martucci C, Wallenstein S, Likourezos Libow LS, Zumoff B (2001) Relationship of sex hormone levels to dependence of daily living in the frail elderly. Maturitas 39:147-159
29. Laumann EO, Paik A, Rosen RC (1999) Sexual dysfunction in the United States: prevalence and predictors. JAMA 281:537-544
30. Meston CM (1997) Aging and sexuality. West J Med 167:285-290
31. Schiavi RC, Schreiner-Engel P, White D, et al (1991) The relationship between pituitary-gonadal function and sexual behavior in healthy aging men. Psychosom Med 53:363-374
32. Johannes CB, Araujo AB, Feldman HA, et al (2000) Incidence of erectile dysfunction in men 40-69 years old: longitudinal results from the Massachusetts Male Aging Study. J Urol 163:460-463
33. Feldman HA, Goldstein I, Hatzichristou DG, et al (1994) Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 151:54-61
34. Korenman SG, Morley JE, Mooradian AD, et al (1990) Secondary hypogonadism in older men: its relation to impotence. J Clin Endocrinol Metab 71:963-969
35. Carani C, Granata ARM, Bancroft J, Marrama P (1995) The effects of testosterone replacement on noctural penile tumescence and rigidity and erectile response to visual erotic stimuli in hypogonadal men. Psychoneuroendocrinology 20:743-753
36. Nickel JC, Morales A, Condra M, et al (1984) Endocrine dysfunction in impotence: incidence, significance and cost-effective screening. J Urol 132:40-46
37. Spivak JL (2000) The blood in systemic disorders. Lancet 355:1707-1712
38. Shahidi NT (1973) Androgens and erythropoiesis. N Engl J Med 289:72-80
39. Barrett-Connor E, Goodman-Gruen D, Patay B (1999) Endogenous sex hormones and cognitive function in older men. J Clin Endocrinol Metab 84:3681-3685
40. Yesavage JA, Davidson J, Widrow L, Berger PA (1985) Plasma testosterone levels, depression, sexuality, and age. Biol Psychiatr 20:222-225
41. Burns AS, Banks SM, Carter CS, et al (1992) A long-term, prospective study of the physiologic and behavioral effects of hormone replacement therapy in untreated hypogonadal men. J Androl 13:297-304
42. Barrett-Connor E, Mühlen DG von, Kriz-Silverstein D (1999) Bioavailable testosterone and depressed mood in older men: The Rancho Bernardo Study. J Clin Endocrinol Metab 84:573-577
43. Flood JF, Farr SA, Kaiser FE, et al (1995) Age-related decrease of plasma testosterone in SAMP8 mice: replacement improves age-related impairment of learning and memory. Physiol Behav 57:669-673
44. Sternbach H (1998) Age-associated testosterone decline in men: clinical issues for psychiatry. Am J Psychiatr 155:1310-1318
45. Hong JH, Ahn TY (2002) Oral testosterone replacement in Korean patients with PADAM. Aging Male 5:52-56
46. Taieb J, Mathian B, Millot F, Patricot M-C, Mathieu E, Queyrel N, Lacroix I, Somma-Delpero C, Boudou P (2003) Testosterone measured by ten immunoassays and by isotope-dilution gas chromatography-mass spectrometry in sera from 116 men, women, and children. Clin Chem 49:1381-1395
47. Morales A, Lunenfeld B (2001) Androgen replacement therapy in aging men with secondary hypogonadism. Draft rec-ommendations for endorsement by ISSAM. Aging Male 4:151
48. Finkelstein JS, Kilbanski A, Neer RM, Doppelt SH, Rosenthal DI, Segre GV, Crowley WF (1989) Increases in bone density during treatment of men with idiopathic hypogonadotrophic hypogonadism. J Clin Endocrinol Metab 69:776
49. Tremblay RR, Morales AJ (1998) Canadian practice recommendations for screening, monitoring and treating men affected by andropause or partial androgen deficiency. Aging Male 1:213
50. Charman WN, Porter CJH (1996) Lipophilic prodrugs designed for intestinal lymphatic tranport. Adv Drug Deliv Rev 19:149-169
51. Noguchi T, Charman WN, Stella VJ (1985) The effect of drug lipophilicity and lipid vehicles on the lymphatic absorption of various testosterone esters. Int J Pharm 173-184
52. Bagchus W, Hust R, Maris F, Schnabel PG, Houwing NS The importance of food for the bioavailability of oral testosterone undecanoeate. (submitted to Pharmacotherapy)
53. Boyanov et al (2003) Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male 6:1-7
54. Yates WR, Perry PJ, MacIndoe J, Holman T, Ellingrod V (1999) Psychosexual effects of 3 doses of testosterone cycling in normal men. Biol Psychiat 45:254-260
55. Marin et al (1992) The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obesity 16:991-997
56. Bebb et al (2001) Abstract presented at Endocrine Society 2001:OR 24-25
57. Wittert et al (2003) Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status. J Gerontol 58A:618-625
58. Gooren L (1986) Long-term safety of the oral androgen testosterone undecanoate. Int J Androl 9:21
59. Köhn, Schill (2003) doi 10.1007/s00345-003-0372-x
60. Sokol RZ, Palacios A, Campfield LA (1982) Comparison of the kinetics of injectable testosterone in eugonadal and hypogonadal men. Fertil Steril 37:425-430
61. Bhasin S (1992) Androgen treatment of hypogonadal men. J Clin Endocrinol Metab 74:1221-1224
62. Morales A, Heaton JWP, Carson CC III (2000) Andropause: a misnomer for a true clinical entity. J Urol 163:705-712
63. Gooren L (2003) doi 10.1007/s00345-003-0364-x
64. Bradwin SW, Swerdloff RS, Santen RJ (1991) Androgens: risks and benefits. J Clin Endocrinol Metab 73:4-7
65. Arver S, Meikle AW, Dobbs AS, et al (1996) Permeation enhanced testosterone transdermal systems in the treatment of male hypogonadism: long term effects. J Endocrinol 148:254-259
66. De Sanctis V, Vullo C, Urso L et al (1999) Clinical experience using Androderm testosterone transdermal system in hypogonadal adolescents and young men with beta-thalassemia major. J Peditr Endocrinol Metab 11 [Suppl 3]:891-900
67. Dobbs AS, Meikle AW, Arver S, et al (1999) Pharmacokinetics, efficacy and safety of permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab 84:3469-3478
68. Wang C, Swerdloff RS, Iranmanesh A, Dobbs A, Snyder PJ, Cunningham G, Matsumoto AM, Weber T, Berman N (2000) Transdermal testosterone gel improves sexual function, mood, muscle strength and body composition parameters in hypogonadal men. J Clin Endocrinol Metab 85:2839
69. Gooren L, Bunck (2003) doi 10.1007/s00345-003-0368-6
70. Zmuda JM, Cauley JA, Kriska A (1997) Longitudinal relation between endogenous testosterone and cardiovascular disease risk factors in middle age men. A 13-year follow-up of former risk factor intervention trial participants. Am J Epidemiol 146:609-615
71. Phillips GB (1994) The association of hypotestosteronemia with coronary artery disease in men. Arterioscler Thromb 14:701-705
72. Uyanik BS, Ari Z, Gumus B, et al (1997) Beneficial effects of testosterone undecanoate on the lipoprotein profiles in healthy elderly men. Jpn Heart J 38:73-77
73. Crook D (2000) Androgens and the risk of cardiovascular disease. Aging Male 3:190
74. Gooren LJG (2001) Visceral obesety, androgens and the risk of cardiovascular disease and diabetes mellitus. Aging Male 4:30
75. Tenover JL (1997) Testosterone and the aging male. J Androl 18:103-106
76. Behre HM (1994) Prostate volume in treated and untreated hypogonadal men in comparison to age matched controls. Clin Endocrinol 40:341-346
77. Cooper CS, Perry PJ, Sparks AE, et al (1998) Effects of exogenous testosterone on prostate volume, serum and semen prostate specific antigen levels in healthy young men. J Urol 159:441-443
78. Holmäng S, Marin P, Lindtstedt G, et al (1993) Effect of long term oral testosterone undecanoate treatment on prostate volume and serum prostate specific antigen in eugonadal middle-aged men. Prostate 23:99-106
79. Nomura A, Heilrunn LK, Stemmermann GN, et al (1998) Prediagnostic serum hormones and the risk of prostate cancer. Cancer Res 48:3515-3520
80. Curran MJ, Bihrle W (1999) Dramatic raise in prostate specific antigen after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate. Urology 53:423-424
81. Wang C, Alexander G, Berman N et al (1996) Testosterone replacement therapy improves mood in hypogonadal men. A clinical research center study. J Clin Endocrin Metab 81:3587-3593
82. Ehrenreich H, Halaris A, Ruether E et al (1999) Psychoendocrine sequelae of chronic testosterone deficiency. J Psychiatr Res 33:379-387
83. Ozata M, Odabasi Z, Caglayan S, et al (1999) Event related male potentials in male hypogonadism. J Endocrinol Invest 22:508-513
84. Sternbach H (1998) Age associated testosterone decline in men: clinical issues for psychiatry. Am J Psychiatr 155:1310-1314
85. Morales A, Connolly J, Burr R, et al (1970) The use of radioactive phosphorous to treat bone pain in metastatic carcinoma of the prostate. Can Med Assoc J 103:372-373
86. Sandbloom RA, Matsumoto AM, Schoene RB, et al (1983) Obstructive sleep apnea syndrome induced by testosterone administration. N Engl J Med 308:508-510
87. Santamaria JD, Prior JC, Fleetham JA (1988) Reversible reproductice dysfunction in men with sleep apnea. Clin Endocrinol (Oxf) 28:461-470
88. Werner AA (1943) The male climacteric: additional observations of 37 patients J. Urol 49:872-882
89. Heller CG, Myers GB (1944) The male climacteric, its symptomatology, diagnosis and treatment. JAMA 126:472-477
90. Marin P, Holmang S, Jonsson L, et al (1992) The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obesity 2:991-997
91. Marin P (1995) Testosterone and regional fat distribution. Obes Res 3:609-612
92. Arver S, Meikle AW, Dobbs AS, et al (1996) Permeation enhanced testosterone transdermal systems in the treatment of male hypogonadism: long-term effects. J Endocrinol 148:254-259
93. Snyder PJ, Peachy H, Hannoush P, et al (1999) Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab 84:2647-2665
94. Snyder PJ, Peachey H, Berlin JA, Hannoush P, Haddad G, Dlewati A, Santanna J, Loh L, Lenrow DA, Holmes JH, Kapoor SC, Atkinson LE, Strom BL (2000) Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 85:2670-2677
95. Tenover JS (1992) Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 75:1092-1098
96. Bebb RA, Wade J, Frohlich J, Basson R, Copp DH (2000) A randomized, double-blind, placebo-controlled trial of testosterone undecanoate administration in aging hypogonadal men: effects on bone density and body composition. Aging Male 3:22-22
97. Wang C, Swerdloff RS, Iranmanesch A, Dobs A, Snyder PJ, Cunningham G, Matsumoto AM, Weber T, Berman N (2000) Transdermal testosterone gel improves sexual function, mood, muscle strenght, and body composition parameters in hypogonadal men. Testosterone Gel Study Group. J Clin Endocrinol Metab 85:2839-2853
98. Wittert GA, Chapman IM, Haren MT, Mackintosh S, Coates P, Morley JE (2003) Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status. J Gerontol 58A:618-625
99. Webb CM, McNeill JG, Hayward CS, de Zeigler D, Collins P (1999) Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation 100:1690-1696
100. Morley JE, Perry HM, Kaiser FE, et al (1993) Effect of testosterone replacement therapy in old hypogonadal males: a preliminary study. J Am Geriatr Soc 41:149-152
101. Hajjar RR, Kaiser FE, Morley JE (1997) Outcomes of long-term testosterone replacement therapy in older hypogonadal males: a retrospective study. J Clin Endocrinol Metab 82:3793-3796
102. Kalintchenko SY, Kozlov GI, Gontcharov NP, Katsiya GV (2003) Oral testosterone undecanoate reverses erectile dysfunction associated with diabetes mellitus in patients failing on sildenafil citrate therapy alone. Aging Male 6:94-99
103. Christiansen K, Kussmann R (1987) Sex hormones and cognitive functions in men. Neuropsychobiology 18:27-36
104. McKeever WF, Deyo A (1990) Testosterone, dihydrotestosterone and spatial task performance of males. Bull Psychonomic Soc 28:305-308
105. Wolf OT, Preut R, Hellhammer DH, Kudielka BM, Schurmeyer TH, Kirschbaum (2000) Testosterone and cognition in elderly men: a single testosterone injection blocks the practice effect in verbal fluency, but has no effect on spatial or verbal memory. Biol Psychiatry 47:650-654
106. Janowsky JS, Oviatt SK, Orwoll ES (1994) Testosterone influences spatial cognition in older men. Behav Neurosci 108:325-332
107. Azad N, Pitale S, Barnes WE, Friedman N (2003) Testosterone treatment enhances regional brain perfusion in hypogonadal men. J Clin Endocrinol Metab 88:3064-3068
108. Behre HM, Kliesch S, Leifke E, Link TM, Nieschlag E (1997) Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 82:2386
109. Hajjar RR, Kaiser FE, Morley JE (1997) Outcomes of long-term testosterone replacement therapy in older hypogonadal males: a retrospective study. J Clin Endocrinol Metab 82:3793-3796
110. Lunenfeld B (2002) The ageing male: demographics and challenges. World J Urol 20:6-11